儿童期起病风湿病中利妥昔单抗相关低丙种球蛋白血症与感染并发症
该单中心回顾性研究纳入2009至2019年波士顿儿童医院85例接受利妥昔单抗治疗的儿童期起病风湿病患者,发现27.1%出现新发低丙种球蛋白血症,25.9%发生感染并发症,其中50%为需住院的严重感染;利妥昔单抗前1个月脉冲糖皮质激素暴露是二者的显著预测因素。
要点
- 利妥昔单抗诱导后18个月内27.1%发生新发低丙种球蛋白血症。
- 利妥昔单抗前1个月脉冲激素显著预测低丙种球蛋白血症和感染并发症。
- 血管炎患者感染并发症(包括严重感染)风险高于其他风湿病。
核心结论
- 多数儿童期起病风湿病患者对利妥昔单抗的感染并发症耐受良好,但相当比例出现新发低丙种球蛋白血症和感染并发症。
- 利妥昔单抗前1个月脉冲糖皮质激素暴露、利妥昔单抗后低丙种球蛋白血症和较年轻用药年龄是重要预测因素。
- 血管炎患者感染并发症(包括严重感染)风险更高。
研究设计与样本
- 单中心回顾性研究,纳入2009至2019年波士顿儿童医院85例6至24岁因儿童期起病风湿病接受利妥昔单抗治疗的患者。
主要发现
- 23例(27.1%)在利妥昔单抗诱导治疗18个月内出现新发低丙种球蛋白血症。
- 调整混杂因素后,利妥昔单抗前1个月脉冲糖皮质激素暴露预测新发低丙种球蛋白血症(OR 3.94;95%CI:1.07,16.0;P=0.044)和感染并发症(OR 15.3;95%CI:3.04,126.8;P=0.003)。
- 利妥昔单抗后低丙种球蛋白血症是严重感染并发症最强预测因素(OR 7.89;95%CI:1.41,65.6;P=0.028)。
- 较年轻用药年龄预测新发低丙种球蛋白血症(OR 0.83;95%CI:0.70,0.97;P=0.021)。
临床怎么用
- 对儿童期起病风湿病患者使用利妥昔单抗时,应警惕低丙种球蛋白血症和感染并发症,尤其是有近期脉冲糖皮质激素暴露、较年轻用药或血管炎的患者。
局限性
- 单中心回顾性研究,样本量85例,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the incidence and risk factors for hypogammaglobulinaemia and infectious complications associated with rituximab treatment in childhood-onset rheumatic diseases. METHODS: We performed a single-centre retrospective study of patients (n = 85) treated at Boston Children's Hospital (BCH) from 2009 to 2019. Study subjects included patients (ages 6-24 years) who received rituximab for the treatment of a childhood-onset rheumatic disease. RESULTS: New-onset hypogammaglobulinaemia developed in 23 (27.1%) patients within 18 months of rituximab induction treatment. Twenty-two patients (25.9%) developed at least one infectious complication in the 18 months following the first rituximab infusion; of these, 11 (50%) had serious infections requiring inpatient treatment. After adjusting for potential confounders, exposure to pulse corticosteroid therapy in the month prior to rituximab use was a significant predictor of both new-onset hypogammaglobulinaemia (odds ratio [OR] 3.94; 95% CI: 1.07, 16.0; P = 0.044) and infectious complications (OR 15.3; 95% CI: 3.04, 126.8; P = 0.003). Post-rituximab hypogammaglobulinaemia was the strongest predictor of serious infectious complications (OR 7.89; 95% CI: 1.41, 65.6; P = 0.028). Younger age at rituximab use was also a significant predictor of new-onset hypogammaglobulinaemia (OR 0.83; 95% CI: 0.70, 0.97; P = 0.021). Compared with other rheumatic diseases, patients with vasculitis had a higher likelihood of developing infectious complications, including serious infections. CONCLUSION: Although rituximab was well tolerated in terms of infectious complications in the majority of patients with childhood-onset rheumatic diseases, a substantial proportion developed new-onset hypogammaglobulinaemia and infectious complications following treatment. Our study highlights a role for heightened vigilance of rituximab-associated hypogammaglobulinaemia and infections in paediatric patients with rheumatic conditions.
引用
- Ong MS, Rothman D, Barmettler S, et al. New-onset hypogammaglobulinaemia and infectious complications associated with rituximab use in childhood-onset rheumatic diseases. Rheumatology (Oxford). 2022. PMID: 34329428. doi:10.1093/rheumatology/keab626
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。